These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Pato MT, Hill JL, Murphy DL. Psychopharmacol Bull; 1990 Jul; 26(2):211-4. PubMed ID: 2236458 [Abstract] [Full Text] [Related]
13. Electroacupuncture for refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial. Zhang ZJ, Wang XY, Tan QR, Jin GX, Yao SM. J Nerv Ment Dis; 2009 Aug; 197(8):619-22. PubMed ID: 19684500 [Abstract] [Full Text] [Related]
15. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature]. Etain B, Bonnet-Perrin E. Encephale; 2001 Jan; 27(3):280-9. PubMed ID: 11488259 [Abstract] [Full Text] [Related]
16. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. Hoehn-Saric R, McLeod DR, Zimmerli WD, Hipsley PA. J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655 [Abstract] [Full Text] [Related]
20. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK. Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647 [Abstract] [Full Text] [Related] Page: [Next] [New Search]